Skip to content
HomeMedia CenterPress releases Global Health EquityFighting For Their Lives: Economist Intelligence Unit Report Finds Patient Groups Lead Global Efforts To Address Hepatitis C

Fighting For Their Lives: Economist Intelligence Unit Report Finds Patient Groups Lead Global Efforts To Address Hepatitis C

New report calls on governments to play their part and improve surveillance, screening and diagnosis of hepatitis C worldwide

Share Article
share to

BEERSE, BELGIUM, 24 June 2014: ‘Tackling hepatitis C: Moving towards an integrated policy approach’, a report published by The Economist Intelligence Unit (EIU) today reveals that many countries around the world have been slow to respond with national policies on hepatitis C despite recent government pledges to fight the disease. The hepatitis C virus remains the leading cause of liver cancer, liver disease and liver transplantation placing a huge burden on patient’s lives and healthcare systems.

Even though incremental progress has been made the report states that, ‘concrete initiatives remain thin on the ground’ because of limited resources, data and information about the impact of hepatitis C. The report finds that despite growing awareness of the disease, epidemiological data remains scarce. This improved awareness underscores the need for a co-ordinated response. However, global variations in prevalence of and approaches to addressing hepatitis C still persist.

Non-government organisations (NGOs) and patient groups are leading the way in raising awareness of hepatitis C and calling for rapid responses from governments.

“People have got to stop asking, ‘should we have a hepatitis programme?’ and start saying ‘when are we going to have one?’” said Charles Gore, president of the World Hepatitis Alliance, who, in the report, makes a case for integrating hepatitis initiatives into already existing programmes such as HIV and cancer. “The 194 countries of the World Health Organisation have provided tangible direction through the recent Resolution on Viral Hepatitis. Now it’s up to national agencies and programmes to work together to develop and implement their own strategies tackling viral hepatitis.”

Viral hepatitis can lead to years of chronic liver infection and kills 1.4 million people annually, a far higher number than previously thought.1 With a peak in hepatitis C-related complications expected in 2020 - 2025, it is imperative to take action now in order to prevent a steep increase in the rate of liver cancer and mortalities associated with the disease. A number of conclusions can be drawn from the report to help achieve this:

  • Surveillance of hepatitis C needs to improve and be integrated into local strategies.
  • Screening and diagnosis must reach vulnerable populations to allow effective prevention and care.
  • Outreach is key to improve awareness of hepatitis C, mobilise stakeholders and ensure coordinated initiatives.

“Countries need to invest in data. They need to be able to identify the problem to be able to tackle it effectively,” said Jack Wallace, executive member of the Coalition to Eradicate Viral Hepatitis in Asia Pacific. “Governments can then develop co-ordinated responses so that everyone is clear about what they need to do, who is responsible and what outcomes they need to measure.”

Hepatitis C is a blood-borne virus which affects as many as 170 million people, or 2.4% of the world’s population.2,3 Despite this, less than half of all countries monitor the chronic form of the disease which can lead to cirrhosis and liver cancer and accounts for 1% of deaths worldwide.1,4

“Whilst it is a positive step forward that hepatitis C is being recognised at a governmental level, the report shows that there is still much to be done to help countries address the disease nationally,” said Gaston Picchio, Global Hepatitis Disease Area Leader, Janssen. “By working with the local hepatitis C communities, Janssen aims to elevate the disease as a serious public health issue and is seeking commitment from everyone involved in the care of these patients to improve healthcare infrastructure and overall outcomes for all those affected.”

Different regions face specific challenges in addressing hepatitis C. For example, Italy’s hepatitis C problem is worst among people over age 40. Whilst Australia has adopted a national hepatitis C strategy, its experience shows that even the most comprehensive policies face challenges in implementation. A lack of sufficient data is one of many obstacles to understanding the true scale of infection in Southeast Asia. And in Latin America, Brazil is leading the way in promoting better access to data, diagnosis and treatment globally as it acts early to establish guidelines and protocols to tackle hepatitis C.

A copy of the EIU report is available at the following link:

This report follows publication of ‘The silent pandemic: Tackling hepatitis C with policy innovation’ in January 2013, which investigated how systemic innovation could minimise the impact of hepatitis C. Both reports were made possible as a result of financial support from Janssen Pharmaceutical NV (Janssen).

About Janssen
Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g. multiple myeloma and prostate cancer), immunology (e.g. psoriasis), neuroscience (e.g. schizophrenia, dementia and pain), infectious disease (e.g. HIV/AIDS, hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g. diabetes). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency.

Janssen believes to effectively fight hepatitis C, a serious commitment is required from all stakeholders to improve the healthcare infrastructure across the continuum of care, increase awareness, provide education and ensure access to effective treatment for people living with hepatitis C. Janssen is working around the world to be a positive catalyst in the fight towards eradication of this deadly disease and serious public health problem.

More information can be found on



  1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-128.
  2. Ford N, Kirby C, Singh K, et al. Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ. 2012;90:540-50.
  3. World Health Organization. Guidance on prevention of viral hepatitis B and C in people who inject drugs. July 2012. Available at: Last accessed June 2014.
  4. World Health Organization. Global policy report on the prevention and control of viral hepatitis in WHO member states. July 2013. Available at: Last accessed June 2014.

Media Inquiries:
Ronan Collins (Global)
Mobile: +47 4884 2500

James Smith-Plenderleith
(Asia Pacific)
Mobile: +852 90220932

Hans Vanavermaete (EMEA)
Mobile: +32 478 447278

Javier Marin
(Latin America)
Mobile: +52 55 53272497

You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.